boost peptides FAQ

Combining GLP-1 therapy with a growth hormone secretagogue or AMPK activator is biologically plausible but requires prescriber oversight due to additive effects on insulin sensitivity and potential hypoglycemia risk. Tirzepatide already produces significant weight loss through appetite suppression. Adding MK-677 would counteract the appetite reduction while potentially preserving lean mass during caloric deficit. The clinical rationale exists, but no published trials have evaluated GLP-1 + GH secretagogue combination therapy in metabolic disease contexts. Any combination protocol should be monitored with fasting glucose, A1C, and body composition assessments at 4–6 week intervals.

Treat it as speculative until Phase 2 human data demonstrate ≥5% REE increases with acceptable safety profiles. Preclinical rodent studies showing metabolic enhancement frequently fail to translate to humans because of species differences in metabolic regulation, receptor density, and pharmacokinetics. MOTS-c is a clear example. Extraordinary mitochondrial effects in mice, but human trials as of 2026 haven't confirmed comparable magnitude of metabolic rate changes. If the peptide lacks peer-reviewed publications in journals like Metabolism, Cell Metabolism, or NEJM, the efficacy claim is unsupported regardless of marketing language.

Growth hormone secretagogues like MK-677 are the most accessible option for increasing REE without reducing appetite. Clinical data show 6–8% energy expenditure increases at 25mg daily doses. The compound stimulates endogenous GH and IGF-1 secretion, enhancing lipolysis and lean mass accrual while simultaneously increasing hunger via ghrelin pathway activation. This makes it unsuitable for calorie-restricted weight loss but effective in contexts where metabolic rate enhancement and muscle preservation are prioritized over appetite control. Dosing must account for individual GH response variability. Some users see diminished returns after 12–16 weeks as the body downregulates GH receptors.

Administer it anyway, but expect a blunted response. The mechanism still functions outside circadian peaks. GnRH receptors in the pituitary don't turn off during the day. But receptor sensitivity and downstream LH secretion are lower during refractory periods between natural pulses. The 2025 Mayo Clinic study found that midday dosing reduced peak testosterone elevation by 35–40% compared to late-evening administration in the same subjects.

GnRH-targeting peptides and growth hormone secretagogues won't produce meaningful testosterone elevation. Primary hypogonadism means the testes can't respond to LH signaling. No amount of upstream stimulation will compensate for non-functional Leydig cells. HCG can produce a partial response if some testicular function remains, but exogenous testosterone replacement is typically required for subjects with complete primary failure.

Testosterone will spike for 7–14 days and then crash below baseline. Continuous GnRH receptor activation causes downregulation. The pituitary stops responding to the signal, LH secretion collapses, and testosterone production follows. This is the mechanism behind GnRH agonist therapy for prostate cancer, where the goal is intentional testosterone suppression. In research settings, pulsatile dosing (mimicking natural GnRH release) is the only way to sustain elevation without triggering desensitization.